Bridging the gap: Challenging lung infections and clinical trial development in cystic fibrosis
Despite the advances with cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, many people living with cystic fibrosis continue to experience lung infections that are challenging to treat.<br/><br/>New treatment options and clinical trial strategies are essential to fill this urgent unmet medical need.
Authors
- Jutta Bend
- Fiona Dunlevy
- D.G. Downey (ORCID: https://orcid.org/0000-0002-6471-549X)
- Lieven Dupont (ORCID: https://orcid.org/0000-0003-3961-1522)
- K. Hill (ORCID: https://orcid.org/0000-0001-5561-8893)
- Nicholas J. Simmonds (ORCID: https://orcid.org/0000-0002-1705-4780)
- Silke van-Koningsbruggen-Rietschel
Institutions
- Queen's University Belfast (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Royal Brompton Hospital (GB)
- Cystic Fibrosis Research Foundation (IT)
- The Cystic Fibrosis Institute (DE)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Journal of Cystic Fibrosis
- Published
- 2024-11-23
- DOI
- https://doi.org/10.1016/j.jcf.2024.11.001
- Citations
- 2
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Queen's University